MYELOSUPPRESSIVE DRUGS
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...13 Aug, 2025, 10.38 AM IST
Load More